"V体育ios版" LncRNA RCAT1 promotes tumor progression and metastasis via miR-214-5p/E2F2 axis in renal cell carcinoma
- PMID: 34244473
- PMCID: PMC8270952
- DOI: VSports在线直播 - 10.1038/s41419-021-03955-7
LncRNA RCAT1 promotes tumor progression and metastasis via miR-214-5p/E2F2 axis in renal cell carcinoma
Abstract
Renal cell carcinoma is the second malignant tumors in the urinary system with high mortality and morbidity. Increasing evidence suggests that long non-coding RNAs (lncRNAs) play critical roles in tumor development and progression. In the current study, based on the publicly available data obtained from GEO and TCGA database, we identified five prognosis-related lncRNAs with the ability to predict the prognosis of patients with renal cell carcinoma. Among them, the uncharacterized and upregulated lncRNA RCAT1 (renal cancer-associated transcript 1) was identified as the key lncRNA. Our data further revealed that the expression of lncRNA RCAT1 was significantly upregulated in renal cell carcinoma tissues and cells VSports手机版. Gain-of-function and loss-of-function studies showed that lncRNA RCAT1 promoted cell proliferation, migration, and invasion in vitro and in vivo. Furthermore, we verified that lncRNA RCAT1 could abundantly sponge miR-214-5p, which served as a tumor suppressor in renal cell carcinoma. Significantly, miR-214-5p overexpression could attenuate the promotion of cell proliferation and metastasis induced by lncRNA RCAT1. Moreover, we found that E2F2 was a direct target of miR-214-5p, and lncRNA RCAT1 could protect E2F2 from miR-214-5p-mediated degradation. Taken together, our findings suggested that lncRNA RCAT1 could enhance the malignant phenotype of renal cell carcinoma cells by modulating miR-214-5p/E2F2 axis, and lncRNA RCAT1 might be a novel prognostic biomarker and a potential therapeutic target for renal cell carcinoma. .
© 2021. The Author(s).
V体育平台登录 - Conflict of interest statement
The authors declare no competing interests.
Figures








"VSports注册入口" References
-
- Hadoux J, Vignot S, De La Motte Rouge T. Renal cell carcinoma: focus on safety and efficacy of temsirolimus. Clin Med Insights Oncol. 2010;4:143–54. doi: 10.4137/CMO.S4482. - VSports最新版本 - DOI - PMC - PubMed
Publication types
MeSH terms
- "V体育安卓版" Actions
- "VSports最新版本" Actions
- Actions (VSports最新版本)
- VSports在线直播 - Actions
- Actions (V体育2025版)
- V体育官网入口 - Actions
- "V体育安卓版" Actions
"V体育安卓版" Substances
Grants and funding
- ZR2019PH077/Natural Science Foundation of Shandong Province (Shandong Provincial Natural Science Foundation)
- "VSports注册入口" ZR2020LZL011/Natural Science Foundation of Shandong Province (Shandong Provincial Natural Science Foundation)
- 82002785/National Natural Science Foundation of China (National Science Foundation of China)
- 81372335/National Natural Science Foundation of China (National Science Foundation of China)
LinkOut - more resources
Full Text Sources
Medical